All News

IV,arm,intravenous,infusion

INVIGORATE-2 Study - IV Secukinumab in Active Psoriatic Arthritis

Jack Cush, MD

The INVIGORATE-2 trial reports that intravenous secukinumab is both effective and safe in patients with active psoriatic arthritis, demonstrating improvements on par with subcutaneous secukinumab.

Read Article
FDA%20approved.jpg (keep)

Bimekizumab FDA Approved for Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis

Jack Cush, MD

UCB announced today that the U.S. Food and Drug Administration (FDA) has approved bimekizumab-bkzx (Bimzelx) for the treatment of 3 chronic inflammatory disorders.

Read Article
RheumNow Podcast square

I Can't Treat Ugly (9.20.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and a new FDA approval for EGPA, this week on the Podcast.

Read Article
PSA068.jpg

FOREMOST: Apremilast in Early Oligoarticular Psoriatic Arthritis

Jack Cush, MD

A controlled trial has shown that apremilast is effective in patients with early, oligoarticular psoriatic arthritis (PsA).

Read Article
Methotrexate

Consensus Guidelines on Pediatric Methotrexate Use

Jack Cush, MD

Methotrexate (MTX) is commonly used in the treatment of pediatric inflammatory skin conditions, often for off-label indications. Consensus based recommendations were published to address 5 major subjects.

Read Article
RheumNow Podcast square

Linger on the Fingers (9.6.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week with a focus on fingers and better prescriptive follow through.

Read Article
antibiotics,pills,capsules

Antibiotics May Increase Inflammatory Arthritis Risk

Jack Cush, MD

A Danish registry study has shown that amongst those patients who develop inflammatory arthritis (IA), antibiotics use was more frequent when compared to the background population (BP). 

Read Article
Korean Epidemiologic study shows the prevalence of Psoriatic arthritis has increased fbetween 2008 and 2020. Prevalence was 6/1000 in 2008 & 19/1000 in 2020. PsA incidence also incr from 3.35 to 5.01/1000 in the same era https://t.co/d20zETK2q2 https://t.co/WAuqoHFDfu

Links:

Dr. John Cush RheumNow ( View Tweet)
Danish cross-sectional survey 12 713 Inflam arthritis (RA, PsA, SpA) pts & found lonliness in one-third (RA 32%; 36% in PsA & SpA) and highest in SpA w/ depression (66%). Loneliness was correlated w/ disease activity. https://t.co/Q3IswbIwe6 https://t.co/GNohOkkmEw

Links:

Dr. John Cush RheumNow ( View Tweet)
Analysis of 5 Nordic registries & 29,478 RA & 10,919 PsA pts initiating 1st bDMARD,s (& 362,087 pop controls). Incident ILD was higher in RA (HR 9.7) & PsA (4.4). but MTX co-use (vs non-use) did not incr ILD in RA (HR 0.9; 0.7, 1.2) or PsA (HR 1.0) https://t.co/xY8COh85Bw https://t.co/weJGirfhDX

Links:

Dr. John Cush RheumNow ( View Tweet)
FOREMOST: Apremilast in Early Oligoarticular Psoriatic Arthritis A controlled trial has shown that apremilast is effective in patients with early, oligoarticular psoriatic arthritis (PsA). https://t.co/i2w4RbGd5f https://t.co/5PD6pYB5vm

Links:

Dr. John Cush RheumNow ( View Tweet)
Yes you can space out Guselkumab injx in controlled Psoriasis. Phase 3b RCT of 149 GUS pts w/ PASI <4 were cont on GUS q8 wks or spaced to q16wks. Noninferiority was shown w/ maintenance of "super-responders" in > 90% w/ both https://t.co/4Y9quetoJn https://t.co/zP9ywFKpvY

Links:

Dr. John Cush RheumNow ( View Tweet)
Swedish population/registry study of incidence of Psoriatic arthritis was estimated at 21.8/100 000 person-years (15.78-28.83/100 000 PY); slightly higher in females, lower w/ higher education, peaks 50-59y. 71% were on DMARD w/in 2 yrs (22% b/ts DMARDs) https://t.co/YTNBHczZ7X https://t.co/KNscF08fKG

Links:

Dr. John Cush RheumNow ( View Tweet)
PsA: Switch or Cycle, the Eternal Question Dr. Aurelie Najm reports on abstracts POS0278 and POS0266 presented at Eular 2024 in Vienna, Austria. https://t.co/xP65pw5zCw https://t.co/T0nBO3HMIP

Links:

Dr. John Cush RheumNow ( View Tweet)
A low risk of Candida infections with ixekizumab (IXE); integrated analysis of 25; Candida infx rates - PsO:1.9/100 PY (N  6892); PsA 2.0/100 PY (N 1401); axSpA 1.2/100PY (N 932). Most occured only once, were mild/moderate & were oral or genital Candida https://t.co/ZkkPoSzPMW https://t.co/VysnaQ8rpi

Links:

Dr. John Cush RheumNow ( View Tweet)
Dactylitis is seen in 50% of PsA patients. Dactylitis is frequently associated with more severe PsA phenotype, often representing the initial feature of the disease. Many agents are effective but no b/tsDMARD is distinguished as being superior in dactylitis.… https://t.co/NKOXReiZYd https://t.co/Ake2fixZ40
Dr. John Cush RheumNow ( View Tweet)
"Vanishing Fingers" Acro-osteolysis in a patient with Scleroderma and renal failure and bilateral hand pain. Causes of AO include Scleroderma, PsA, hypertrophic osteoarthropathy, skeletal dysplasias, frostbite, Hyperparathyroidism, genetic disorders https://t.co/UwXcw3r6LD https://t.co/bnGiY0i0ot

Links:

Dr. John Cush RheumNow ( View Tweet)
Causes of Carpal Tunnel Syndr: obesity, repetitive wrist movements, pregnancy, RA, PsA. but also Sjögren's syndrome, Behcet's disease and systemic sclerosis (weaker) https://t.co/ssrs8UJEpX

Links:

Dr. John Cush RheumNow ( View Tweet)

Studies on Psoriatic Arthritis Prevention PsA is a sequelae to chronic skin psoriasis. Whether cutaneous psoriasis is the pre-clinical phase of what may become PsA is oft debated and has been inadequately researched. https://t.co/5ESROnS6xk https://t.co/8Yte7JESZf

Links:

Dr. John Cush RheumNow ( View Tweet)
Tyk2 inhibitor/Zasocitinib (TAK-279) effective in Psoriasis. Ph II RDBPCT of 259 pts w/ mod- severe plaque PsO showed 12 week PASI 75 success in 68% & 67% on 15 - 30 mg zasocitinib qd vs Placebo (18%). https://t.co/yyZwBYAP3H https://t.co/TvSSlEAKtR

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×